Hanmi Pharm Co Ltd (128940.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7128940004
Hanmi Pharm Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.50 tn KRW | 1.55 tn KRW |
| Gross profit | 817.04 bn KRW | 884.41 bn KRW |
| Operating income | 216.19 bn KRW | 257.80 bn KRW |
| EBIT | 195.63 bn KRW | 230.46 bn KRW |
| Net income | 121.32 bn KRW | 169.55 bn KRW |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
More stocks
- Bethel Automotive Safety Systems Co Ltd Class A (603596.SS)
- TravelSky Technology Ltd (696.HK)
- Dormakaba Holding AG (DOKA.SW)
- Kobayashi Pharmaceutical Co Ltd (4967.T)
- AMERICAN STATES WATER CO (AWR)
- SIMMONS FIRST NATIONAL CORP (SFNC)
- HIGHWOODS PROPERTIES, INC. (HIW)
- Broadstone Net Lease, Inc. (BNL)
- Anhui Yingliu (603308.SS)
- StoneCo Ltd (STNE)
- Cirsa Enterprises SAU (CIRSA.MC)
- Anxin Trust Co Ltd (600816.SS)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.